PMID- 9144315
OWN - NLM
STAT- MEDLINE
DCOM- 19970806
LR  - 20211203
IS  - 0300-8177 (Print)
IS  - 0300-8177 (Linking)
VI  - 170
IP  - 1-2
DP  - 1997 May
TI  - Differential effect of glucose deprivation on MAPK activation in drug sensitive 
      human breast carcinoma MCF-7 and multidrug resistant MCF-7/ADR cells.
PG  - 23-30
AB  - We have investigated the effect of glucose deprivation treatment on the 
      activation of mitogen activated protein kinases (MAPKs) in the drug-sensitive 
      human breast carcinoma cells (MCF-7) and its drug resistant variant (MCF-7/ADR) 
      cells. Western blots and in-gel kinase assays showed that glucose free medium was 
      a strong stimulus for the activation of MAPK in MCF-7/ADR cells. No activation 
      was seen in MCF-7 cells. MAPK was activated within 3 min of being in glucose free 
      medium and it remained activated for over 1 h in MCF-7/ADR cells. After being 
      returned to complete medium, 1 h was required for the MAPK to become deactivated. 
      To investigate whether alternative sources of ATP could inhibit glucose 
      deprivation induced MAPK activation, we added glutamine and glutamate to glucose 
      deprived medium. The addition of glutamine did not reverse glucose deprivation 
      induced MAPK activation in MCF-7/ADR cells. The addition of glutamate, however, 
      decreased the MAPK activation and the length of time of activation. We observed 
      an increase greater than three fold in MEK, Raf, Ras, and PKC activity with 
      glucose deprivation in MCF-7/ADR cells. This suggests that glucose 
      deprivation-induced MAPK activation is mediated through this signal transduction 
      pathway.
FAU - Gupta, A K
AU  - Gupta AK
AD  - Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan 
      48073, USA.
FAU - Lee, Y J
AU  - Lee YJ
FAU - Galoforo, S S
AU  - Galoforo SS
FAU - Berns, C M
AU  - Berns CM
FAU - Martinez, A A
AU  - Martinez AA
FAU - Corry, P M
AU  - Corry PM
FAU - Wu, X
AU  - Wu X
FAU - Guan, K L
AU  - Guan KL
LA  - eng
GR  - CA44550/CA/NCI NIH HHS/United States
GR  - CA48000/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0RH81L854J (Glutamine)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-raf)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinase 1)
RN  - EC 2.7.11.25 (MAP3K1 protein, human)
RN  - EC 3.6.5.2 (ras Proteins)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Breast Neoplasms
MH  - Calcium-Calmodulin-Dependent Protein Kinases/*metabolism
MH  - Cell Line
MH  - Doxorubicin/toxicity
MH  - *Drug Resistance, Multiple
MH  - Enzyme Activation/drug effects
MH  - Female
MH  - Glucose/*pharmacology
MH  - Glutamic Acid/pharmacology
MH  - Glutamine/pharmacology
MH  - Humans
MH  - Kinetics
MH  - *MAP Kinase Kinase Kinase 1
MH  - Protein Kinase C/metabolism
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-raf
MH  - Signal Transduction
MH  - Tumor Cells, Cultured
MH  - ras Proteins/metabolism
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1023/a:1006890316102 [doi]
PST - ppublish
SO  - Mol Cell Biochem. 1997 May;170(1-2):23-30. doi: 10.1023/a:1006890316102.